Volume 11 Issue 6
Dec.  2021
Turn off MathJax
Article Contents
Huiya Yuan, Shihui Yu, Guihong Chai, Junting Liu, Qi (Tony) Zhou. An LC-MS/MS method for simultaneous analysis of the cystic fibrosis therapeutic drugs colistin, ivacaftor and ciprofloxacin[J]. Journal of Pharmaceutical Analysis, 2021, 11(6): 732-738. doi: 10.1016/j.jpha.2021.02.004
Citation: Huiya Yuan, Shihui Yu, Guihong Chai, Junting Liu, Qi (Tony) Zhou. An LC-MS/MS method for simultaneous analysis of the cystic fibrosis therapeutic drugs colistin, ivacaftor and ciprofloxacin[J]. Journal of Pharmaceutical Analysis, 2021, 11(6): 732-738. doi: 10.1016/j.jpha.2021.02.004

An LC-MS/MS method for simultaneous analysis of the cystic fibrosis therapeutic drugs colistin, ivacaftor and ciprofloxacin

doi: 10.1016/j.jpha.2021.02.004
Funds:

Research reported in this publication was supported by the National Institute of Health's National Institute of Allergy and Infectious Diseases under Award Nos. R01AI146160 and R01AI132681. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Health.

  • Received Date: Jun. 01, 2020
  • Accepted Date: Feb. 22, 2021
  • Rev Recd Date: Jan. 25, 2021
  • Available Online: Jan. 12, 2022
  • Publish Date: Dec. 15, 2021
  • Inhaled antibiotics such as colistin and ciprofloxacin are increasingly used to treat bacterial lung infections in cystic fibrosis patients. In this study, we established and validated a new HPLC-MS/MS method that could simultaneously detect drug concentrations of ciprofloxacin, colistin and ivacaftor in rat plasma, human epithelial cell lysate, cell culture medium, and drug transport media. An aliquot of 200 μL drug-containing rat plasma or cell culture medium was treated with 600 μL of extraction solution (acetonitrile containing 0.1% formic acid and 0.2% trifluoroacetic acid (TFA)). The addition of 0.2% TFA helped to break the drug-protein bonds. Moreover, the addition of 0.1% formic acid to the transport medium and cell lysate samples could significantly improve the response and reproducibility. After vortexing and centrifuging, the sample components were analyzed by HPLC-MS/MS. The multiple reaction monitoring mode was used to detect the following transitions: 585.5–101.1 (colistin A), 578.5–101.1 (colistin B), 393.2–337.2 (ivacaftor), 332.2–314.2 (ciprofloxacin), 602.3–101.1 (polymyxin B1 as internal standard (IS)) and 595.4–101.1 (polymyxin B2 as IS). The running time of a single sample was only 6 min, making this a time-efficient method. Linear correlations were found for colistin A at 0.029–5.82 μg/mL, colistin B at 0.016–3.14 μg/mL, ivacaftor at 0.05–10.0 μg/mL, and ciprofloxacin at 0.043–8.58 μg/mL. Accuracy, precision, and stability of the method were within the acceptable range. This method would be highly useful for research on cytotoxicity, animal pharmacokinetics, and in vitro drug delivery.
  • loading
  • J.L. Bobadilla, M. Macek, J.P. Fine, etal Cystic fibrosis: a worldwide analysis of CFTR mutations-correlation with incidence data and application to screening, Hum. Mutat. 19(6) (2002) 575-606
    K. De Boeck, F. Vermeulen, L. Dupont. The diagnosis of cystic fibrosis, Presse Med. 46(6) (2017) E97-E108
    D. Goetz, C. Ren. Review of cystic fibrosis, Pediatr. Ann. 48(4) (2019) E154-E161
    K. De Boeck, Cystic fibrosis in the year 2020: a disease with a new face, Acta Paediatr. 109 (2020) 893-899.
    A. Schick, R. Kassen. Rapid diversification of Pseudomonas aeruginosa in cystic fibrosis lung-like conditions, Proc. Natl. Acad. Sci. U.S.A. 115(42) (2018) 10714-10719
    B. Millar, J. Rendall, D. Downey, etal Does ivacaftor interfere with the antimicrobial activity of commonly used antibiotics against Pseudomonas aeruginosa?-Results of an in vitro study, J. Clin. Pharm. Therapeut. 43(6) (2018) 836-843
    D. Hubert, R. Chiron, B. Camara, D, etal Real-life initiation of lumacaftor/ivacaftor combination in adults with cystic fibrosis homozygous for the Phe508del CFTR mutation and severe lung disease, J. Cyst. Fibros. 16(3) (2017) 388-391
    Y.-H. Liu, S.-C. Kuo, B.-Y. Yao, Z, etal Colistin nanoparticle assembly by coacervate complexation with polyanionic peptides for treating drug-resistant gram-negative bacteria, Acta Biomater. 82 (2018) 133-142
    W.T. Barker, S.E. Martin, C.E. Chandler, etal Small molecule adjuvants that suppress both chromosomal and mcr-1 encoded colistin-resistance and amplify colistin efficacy in polymyxin-susceptible bacteria, Bioorg. Med. Chem. 25(20) (2017) 5749-5753
    J.M. Buyck, P.M. Tulkens, F. Van Bambeke, Activities of antibiotic combinations against resistant strains of Pseudomonas aeruginosa in a model of infected THP-1 monocytes, Antimicrob. Agents Chemother. 59(1) (2015) 258
    A. Rehman, W. Patrick, I. Lamont, Mechanisms of ciprofloxacin resistance in Pseudomonas aeruginosa: new approaches to an old problem, J. Med. Microbiol. 68(1) (2019) 1-10
    T.B. Tran, T. Velkov, R.L. Nation, etal Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet? Int. J. Antimicrob. 48(6) (2016) 592-597
    N. Hoeiby, B. Frederiksen, T. Pressler, Eradication of early Pseudomonas aeruginosa infection, J. Cyst. Fibros. 4(2) (2005) 49-54
    L.R. Reznikov, M.H. Abou Alaiwa, C.L. Dohrn, etal Antibacterial properties of the CFTR potentiator ivacaftor, J. Cyst. Fibros. 13(5) (2014) 515-519
    E.K. Schneider, M.A. Azad, M.-L. Han, etal An “unlikely” pair: the antimicrobial synergy of polymyxin B in combination with the cystic fibrosis transmembrane conductance regulator drugs KALYDECO and ORKAMBI, ACS Infect. Dis. 2(7) (2016) 478-488
    J. Li, R.W. Milne, R.L. Nation, J.D. Turnidge, etal A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography, J. Chromatogr. 761(2) (2001) 167-175
    F. Ratjen, H. Beier, H. Grasemann, Pharmacokinetics of inhaled colistin in patients with cystic fibrosis: authors' response, J. Antimicrob. Chemother. 58(1) (2006) 223-223
    B. Jansson, M. Karvanen, O. Cars, etal Quantitative analysis of colistin A and colistin B in plasma and culture medium using a simple precipitation step followed by LC/MS/MS, J. Pharmaceut. Biomed. Anal. 49(3) (2009) 760-767
    M. Leporati, R.O. Bua, F. Mariano, etal Determination by LC-MS/MS of colistins A and B in plasma and ultrafiltrate from critically ill patients undergoing continuous venovenous hemodiafiltration, Ther. Drug Monit. 36(2) (2014) 182-191
    I.L. Tsai, H.-Y. Sun, G.-Y. Chen, etal Simultaneous quantification of antimicrobial agents for multidrug-resistant bacterial infections in human plasma by ultra-high-pressure liquid chromatography-tandem mass spectrometry, Talanta. 116 (2013) 593-603
    E.K. Schneider, F. Reyes-Ortega, J.W. Wilson, etal Development of HPLC and LC-MS/MS methods for the analysis of ivacaftor, its major metabolites and lumacaftor in plasma and sputum of cystic fibrosis patients treated with ORKAMBI or KALYDECO, J. Chromatogr. 1038 (2016) 57-62
    Z. Ma, J. Wang, J.P. Gerber, etal Determination of colistin in human plasma, urine and other biological samples using LC-MS/MS, J. Chromatogr. 862(1-2) (2008) 205
    D.W.-M. Sin, C. Ho, Y.-C. Wong, etal Analysis of major components of residual bacitracin and colistin in food samples by liquid chromatography tandem mass spectrometry, Anal. Chim. Acta 535(1) (2005) 23-31
    H.X. Ong, D. Traini, P.M. Young, Pharmaceutical applications of the Calu-3 lung epithelia cell line, Expert Opin. Drug Deliv. 10(9) (2013) 1287-1302
    G. Chai, H. Park, S. Yu, etal Evaluation of co-delivery of colistin and ciprofloxacin in liposomes using an in vitro human lung epithelial cell model, Int. J. Pharm. 569 (2019)
    D. Decolin, P. Leroy, A. Nicolas, etal Hyphenated liquid chromatographic method for the determination of colistin residues in bovine tissues, J. Chromatogr. Sci. 35(12) (1997) 557-564
    Y. Dotsikas, C. Markopoulou, J. Koundourellis, etal Validation of a novel LC-MS/MS method for the quantitation of colistin A and B in human plasma, J. Separ. Sci. 34(1) (2011) 37-45
    C. Govaerts, J. Rozenski, J. Orwa, etal Mass spectrometric fragmentation of cyclic peptides belonging to the polymyxin and colistin antibiotics studied by ion trap and quadrupole/orthogonal-acceleration time-of-flight technology, Rapid Commun. Mass Spectrom. 16(9) (2002) 823-833
    C. Govaerts, J. Orwa, A.V. Schepdael, etal Characterization of polypeptide antibiotics of the polymyxin series by liquid chromatography electrospray ionization ion trap tandem mass spectrometry, J. Pept. Sci. 8(2) (2002) 45-55
    E. Caro, R.M. Marce, P.A.G. Cormack, etal Direct determination of ciprofloxacin by mass spectrometry after a two-step solid-phase extraction using a molecularly imprinted polymer, J. Sep.Sci. 29(9) (2006) 1230-1236
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (214) PDF downloads(11) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return